Related Experiment Video
Updated: Dec 31, 2025

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice
Published on: February 22, 2019
Assessing adolescent immunization options for pertussis in Canada: A cost-utility analysis
Kika Anyiwe1, Marina Richardson1, Jason Brophy2
1Institute of Health Policy, Management and Evaluation, University of Toronto, 155 College Street, Toronto, ON M5T 3M6, Canada; Toronto Health Economics and Technology Assessment (THETA) Collaborative, Toronto General Hospital, University Health Network, 200 Elizabeth Street, Toronto, ON M5G 2C4, Canada.
Optimizing tetanus, diphtheria, and pertussis (Tdap) immunization timing in adolescents is key for pertussis prevention. Study findings suggest immunizing at age 10 or removing the adolescent vaccine is more cost-effective than the current practice.
Area of Science:
- Public Health
- Epidemiology
- Health Economics
Background:
- Adolescent tetanus, diphtheria, and pertussis (Tdap) immunization is crucial for preventing pertussis.
- The timing of Tdap vaccine administration significantly impacts disease prevention and associated costs.
- Assessing cost-utility of different adolescent Tdap immunization schedules is vital for Canadian healthcare policy.
Purpose of the Study:
- To evaluate the cost-utility of various adolescent Tdap immunization strategies in Canada.
- To compare the economic impact of immunizing at age 10, age 14 (status quo), or removing adolescent vaccination.
- To inform optimal Tdap vaccination policies for adolescents.
Main Methods:
- A cost-utility analysis using a Markov model simulating pertussis disease progression in adolescents (starting at age 10).
- Comparison of three strategies: 10-year-old immunization, 14-year-old immunization (status quo), and no adolescent vaccination.
- Analysis from a healthcare payer perspective over a lifetime horizon, with a 1.5% discount rate for costs and outcomes.
Main Results:
- The current strategy of immunizing 14-year-olds yielded 40.44 QALYs and cost $26.28 per individual.
- Immunization at age 10 dominated the 14-year-old strategy and was cost-effective compared to no immunization (ICER $74,899/QALY).
- Removing adolescent vaccination was the most cost-effective strategy in 78% of simulations at a $50,000/QALY threshold, with sensitivity analyses highlighting pertussis incidence and severity as key factors.
Conclusions:
- Alternate adolescent Tdap vaccination strategies, specifically immunization at age 10 or removal of the adolescent vaccine, are more cost-effective than the current practice of immunizing at age 14.
- These findings support policy considerations for optimizing adolescent Tdap immunization schedules in Canada.
- The analysis assumes concurrent recommendation of maternal Tdap immunization.
More Related Videos
06:26Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis
Published on: July 28, 2023
06:16Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
Published on: August 9, 2024
Related Concept Videos
Vaccinations
Pneumonia III: Complications and Assessment
Drug Dosing: Infants and Children
Dosage Regimens: Designs and Approaches
Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...